Goldman Hikes Revvity Target, Shares Surge

Revvity Inc., a US-based life sciences company, saw its stock price close at $143.45 on the New York Stock Exchange (NYSE) on September 21, 2026.

The move comes after Goldman Sachs increased its target price for Revvity from $100 to $140 while maintaining a Neutral rating.

This follows a week in which shares of Revvity had gained 15.40% and have risen 63.91% over the past year, according to Morningstar's assessment on September 21.

The S&P 500 closed at $7,764.70 that day, up 1.49%, providing a broader market context for Revvity's performance.